Coronavirus: rheumatism drugs more take – Naturopathy naturopathy specialist portal

Rheumatic: drugs not settle out of fear of Coronavirus

The novel Coronavirus SARS-CoV-2 spreads still further. People who suffer from rheumatism, have infection due to the weakened immune system often have special afraid. Experts point out that this fear must not, however, cause that data to sell their drugs.

According to previous estimates by the Robert Koch-Institute (RKI) have patients with auto-declared immune a weakened immune system (for example, by taking medications that weaken the immune system) diseases, such as inflammatory rheumatism often and are therefore subject to generally increased risk for severe COVID-19-gradients, of the German rheumatism-League. Nevertheless, Sufferers should not stop your medication out of fear of SARS-CoV-2.

Therapy continue unchanged

As the German society of rheumatology e. V. (DGRh) writes in a recent communication, examine Researchers worldwide, as infection with the novel Coronavirus SARS-CoV-2 affects patients with inflammatory rheumatic diseases.

“Whether patients with inflammatory rheumatic diseases are particularly at risk of being infected with the Virus, and whether you have, in the case of infection – an increased risk for a severe course of the viral disease, is today largely unknown,” explains Professor Dr. med. Hendrik Schulze-Koops, President of the DGRh.

The society advises Affected with inflammatory rheumatic diseases therefore, like all other patients, the distance and the hygiene recommendations of the RKI must be strictly observed.

At the same time, the DGRh patients recommends the therapy for their rheumatic disease unchanged to continue, as long as no infection with the Virus is detected and you have no symptoms of a COVID-19-have the disease.

“The concern is well-founded, that a rheumatic disease could become active again and then to the therapy, even higher amounts of immunosuppressive drugs, such as cortisone, are necessary,” said Professor Schulze-Koops.

Affected were less likely to show symptoms of respiratory diseases

According to the DGRh under an analysis of the University of Erlangen in cooperation with the clinics for rheumatology, gastroenterology and dermatology looked at patients under the ongoing treatment of an inflammatory gastroenterological, rheumatological or dermatological disorder is the Occurrence of antibodies against SARS-CoV-2.

In the blood of the anti-flammable treated individuals rare antibody against SARS-CoV-2 were detected as in the case of two control groups – in the case of employees of the health system and the healthy, not the health system’s workforce.

In addition, treated patients and patients with biologics in the period from February to April 2020 rare symptoms of respiratory diseases.

No particular risk group

The study authors concluded from these observations that the patients under biologic therapy are not at increased risk of infection with SARS-CoV-2 compared to the two control groups.

They concluded that in these patients, infection with SARS-CoV-2 runs may be less difficult.

The authors support their findings, the recommendations of the DGRh in the sense that patients under the ongoing treatment of your inflammatory rheumatological, dermatological, or gastroenterological disease, there is no special risk group, and therefore, the therapy alone for fear of an infection with SARS-CoV-2 should not settle.

Dangerous Conclusion

The press release of the University of Erlangen derived from the results that patients with inflammatory diseases were protected by their therapy in front of a SARS-CoV-2 infection and a severe course of the COVID-19-disease.

The DGRh sees this conclusion, however, as unfounded and dangerous. Together with the authors of the study, the expressly distance themselves from this Interpretation, the DGRh, therefore, that the data from the study are reassuring in terms of risk of SARS-CoV-2 infection and the course of a COVID-19 disease.

You to have but not a conclusion to the effect that patients with inflammatory rheumatological, gastro-entero-protected logical or dermatological disorders by their treatment of an infection or a potentially fatal course of a COVID-19 infection.

Hygiene and distance recommendations follow

Patients with inflammatory rheumatic, gastroenterological, and dermatological disorders should follow, therefore, still consistently the Hygiene and spacing recommendations of the RKI.

It consists of the data from Gain point again – no need to have a current therapy for the fear of a SARS-CoV-2 infection to interrupt.

“But there is no reason to be in the current Situation, careless, or even biologics without a medical indication for protection against a SARS-CoV-2 infection or a severe course of a COVID-19-disease”, said the Executive Board of the DGRh. (ad)